导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.74% | 3387/4773 |
| 近一周 | -3.57% | 4823/5465 |
| 近一月 | -4.15% | 3069/5421 |
| 近一季 | -3.91% | 1710/5231 |
| 近半年 | -8.32% | 3487/4920 |
| 近一年 | -3.40% | 3102/4394 |
| 近两年 | 34.59% | 2117/2954 |
| 近三年 | 10.60% | 1742/2253 |
| 成立以来 | 148.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.53% 2349/4961 |
0.12% 3207/5312 |
- - |
- - |
| 2025 | 13.38% 2645/4813 |
-0.67% 2348/3635 |
-2.11% 3312/4076 |
17.57% 2470/4524 |
-0.82% 2662/4813 |
| 2024 | 11.45% 1321/3463 |
2.62% 740/2808 |
-4.09% 1465/3014 |
19.36% 852/3129 |
-5.13% 2533/3463 |
| 2023 | -5.60% 755/2656 |
6.69% 657/2280 |
-4.85% 1307/2385 |
0.13% 383/2515 |
-7.13% 2065/2655 |
| 2022 | -18.21% 677/2207 |
-10.79% 424/1919 |
2.00% 1386/2016 |
-12.77% 780/2113 |
3.04% 780/2208 |
| 2021 | -2.88% 876/1822 |
0.98% 266/1255 |
-0.97% 1154/1330 |
-2.36% 569/1466 |
-0.54% 1248/1822 |
| 2020 | 25.12% 622/1250 |
-12.20% 876/1028 |
12.56% 681/1067 |
11.21% 468/1164 |
13.84% 328/1184 |
| 2019 | 49.28% 107/1092 |
36.24% 88/754 |
-2.18% 344/804 |
0.23% 543/850 |
11.75% 47/918 |
| 2018 | -26.44% 384/834 |
- - |
- - |
- - |
-10.09% 176/691 |
| 2017 | 35.32% 36/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.89% 185/605 |
- - |
- - |
- - |
- - |
| 2015 | 21.85% 108/575 |
- - |
- - |
- - |
- - |
| 2014 | 53.32% 64/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.49% 98/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.94% 107/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实深证基本面120ETF VS. 长安沪深300非周期A(740101) |